Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Biotechnology

Healthcare
$75.95 +0.46%

+$0.29 today

Market cap
$3.74B
Beta
0.51
P/E (TTM)
-55.9
EPS (TTM)
-$1.12
52W Low $38.51High $85.25

Volume 0.45M

Average 0.61M

TARS Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Tarsus Pharmaceuticals, Inc.NASDAQ: TARS

Income Tax Expense · Q3 FY2026 · quarter ended Sep 2026

Income tax expense turns negative

Q3 FY2026 income tax expense was -$4.64M, compared with $0 a year earlier. Trailing-twelve-month income tax expense was -$2.22M.

Context

  • Income tax expense amounted to 0.5% of revenue in FY2025, up 0.5 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income tax expense holds near -$4.64M or moves back toward the trailing-twelve-month quarterly average of -$554.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$4.64M-270.9% QoQ
Last fiscal yearDec 2025
$2.06M— YoY
LTMSep 2026
-$2.22M— YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
2.06M USD
Year-over-year change
—
4-year CAGR
+147.4%

Income Tax Expense vs competitors

How TARS compares with its peers on the latest reported figures

  • TARS's LTM Sep 2026 income tax expense of -$2.22M is the lowest of the 6 companies compared; the peer median is $0.
  • Income tax expense amounts to 0.3% of revenue for TARS, versus a peer median of 0.1%.
TARS Competitors Peer median
Income Tax Expense for TARS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
HROWHarrow Health, Inc.LTM Mar 2026$3.8M +2257.8%+257.1%1.4%
ARQTArcutis Biotherapeutics, Inc.LTM Jun 2026$779K -17.5%—0.2%
TTRXTurn Therapeutics Inc.LTM Mar 2026$0 ———
SLGLSol-Gel Technologies Ltd.LTM Mar 2026$0 ——0.0%
VRCAVerrica Pharmaceuticals Inc.LTM Mar 2026$0 ——0.0%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026-$2.22M ——0.3%
Peer median (excluding TARS) $0+1120.1%+257.1%0.1%

Competitors are the stored peer set for TARS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue57.03M25.82M17.45M182.95M451.36M
Cost of Revenue2.08M955K1.59M12.83M30.68M
Gross Profit54.95M24.86M15.85M170.13M420.68M
Gross Margin96.4%96.3%90.9%93.0%93.2%
Research & Development41.71M42.62M50.31M53.39M64.32M
Selling, General & Admin25.4M44.95M108.7M237.31M427.32M
Operating Expenses67.11M87.57M159.01M290.7M491.65M
Depreciation & Amortization312K326K877K1.23M1.82M
EBITDA(13.46M)(59.71M)(131.67M)(106.48M)(53.61M)
EBITDA Margin-23.6%-231.3%-754.7%-58.2%-11.9%
Operating Income(12.16M)(62.71M)(143.16M)(120.57M)(70.97M)
Operating Margin-21.3%-242.9%-820.5%-65.9%-15.7%
Interest Income36K3.5M10.34M15.01M15.75M
Interest Expense02.06M3.23M7.45M8.94M
Other Income / Expenses(1.62M)617K7.27M5.02M6.61M
Income Before Tax(13.77M)(62.1M)(135.89M)(115.55M)(64.36M)
Pre-Tax Margin-24.1%-240.5%-778.9%-63.2%-14.3%
Income Tax Expense55K(4K)002.06M
Net Income(13.83M)(62.09M)(135.89M)(115.55M)(66.42M)
Net Margin-24.2%-240.5%-778.9%-63.2%-14.7%
EPS (Basic)(0.67)(2.52)(4.62)(3.07)(1.59)
EPS (Diluted)(0.67)(2.52)(4.62)(3.07)(1.59)
Weighted Avg Shares20.55M24.62M29.38M37.6M41.78M
Weighted Avg Shares (Diluted)20.55M24.62M29.38M37.6M41.78M

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

Intrinsic Alpha fair value

Locked

Current Price

$75.95

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.